8-Epidiosbulbin E acetate

CAS No. 91095-48-6

8-Epidiosbulbin E acetate ( —— )

Catalog No. M24951 CAS No. 91095-48-6

8-Epidiosbulbin E acetate exhibits broad-spectrum plasmid-curing activity against multidrug-resistant (MDR) bacteria, including vancomycin-resistant enterococci.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 195 In Stock
10MG 288 In Stock
25MG 484 In Stock
50MG 701 In Stock
100MG 981 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    8-Epidiosbulbin E acetate
  • Note
    Research use only, not for human use.
  • Brief Description
    8-Epidiosbulbin E acetate exhibits broad-spectrum plasmid-curing activity against multidrug-resistant (MDR) bacteria, including vancomycin-resistant enterococci.
  • Description
    8-Epidiosbulbin E acetate exhibits broad-spectrum plasmid-curing activity against multidrug-resistant (MDR) bacteria, including vancomycin-resistant enterococci.
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    Antifection
  • Recptor
    Anti-infection
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    91095-48-6
  • Formula Weight
    388.4
  • Molecular Formula
    C21H24O7
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C[C@](C[C@@H](c1cocc1)O1)([C@H](C[C@H](C[C@H]23)OC2=O)[C@@H]3[C@H](C2)OC(C)=O)[C@H]2C1=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.A potential plasmid-curing agent, 8-epidiosbulbin E acetate, from Dioscorea bulbifera L. against multidrug-resistant bacteria.Int J Antimicrob Agents. 2008 Nov;32(5):405-10.
molnova catalog
related products
  • Dextrothyroxine

    Dextrothyroxine could lower cholesterol and also increases hepatic lipase which in turn improves utilization of triglycerides, leading to improve apolipoprotein E cholesterol particles.

  • Rilematovir

    JNJ-678 is a novel inhibitor of the fusion protein. JNJ-678 shows the potential for respiratory syncytial virus (RSV) treatment.

  • Chimonanthine

    (-)-Chimonanthine (IC50 = 0.93 μM) shows potent inhibitory effects on melanogenesis in theophylline-stimulated murine B16 melanoma 4A5 cells.